Clinical trials: Ganglion
Parkinson Disease
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
The underlying goal of this study is to assess [18F]MPPF PET imaging as a tool to evaluate the activity of the serotonin 5HT1a receptor in the brain of Parkinson Disease (PD) research participants.
- Trial name
- MPPF (NCT01461083)
- Testing
- [18F]MPPF
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Huntington's Disease
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites…
- Trial name
- NCT01574053
- Where
- 183 sites in United States, Argentina and 18 more
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.
Parkinson's Disease
Superior Colliculus Activity in Parkinson Disease: a Potential Marker?
The ultimate goal of this project is to evaluate a possible new strategy to diagnose earlier Parkinson's disease, using the superior colliculus as a biomarker.
- Trial name
- AGIRPARK (NCT02488395)
- Testing
- fMRI, Ophthalmologic evaluation, visual psychophysics test
- Where
- 3 sites in France
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Parkinson Disease
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
- Trial name
- NCT01536366
- Testing
- BIA 9-1067, Repaglinide
- Where
- Portugal
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Huntington Disease, Hereditary Breast and Ovarian Cancer
Genetic Risk: Whether, When, and How to Tell Adolescents
This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for…
- Conditions
- Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer
- Trial name
- NCT03421327
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Parkinson Disease, Alexithymia
Visuospatial and Affective Abilities in Parkinson Disease
The aim of the study is to investigate whether prismatic adaptation (PA) and virtual prismatic adaptation (VPA), a non-invasive neuromodulation technique, that involves the use of lenses that deviate the visual field, can…
- Conditions
- Parkinson Disease, Alexithymia, Visuospatial/Perceptual Abilities
- Trial name
- NCT06341829
- Testing
- Prismatic adaptation, Schirmer test
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Parkinson Disease
Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine
Lewy Body Dementia (LBD), is the second most common form of dementia after Alzheimer's Disease. Dementia is defined as a serious loss in cognitive ability due to damages or disease in the brain beyond what is normal aging.
- Trial name
- NCT03858270
- Testing
- Memantine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Wayne State University
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
- Trial name
- NCT05523570
- Testing
- HNC364
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson
Impact of Exercise on Muscle Metabolism and Function for Persons With Parkinsons
This investigation assesses the impact of a strengthening program on muscle metabolism in the gastrocnemius muscle (GM) and is an essential step in the establishment of future clinical intervention for the GM in people with…
- Trial name
- NCT07720713
- Testing
- Home Exercise Program
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Vascular Parkinsonism, Parkinson's Disease
Differences Between Patients With Vascular Parkinsonism and Parkinson's Disease
Vascular parkinsonism (VP) is defined as the presence of parkinsonian syndrome, evidence of cerebrovascular disease by brain imaging and an established relationship between the two disorders.
- Trial name
- NCT04308135
- Testing
- Neuro-radiological tools:, cognitive tests, lab investigations
- Where
- Egypt
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Alzheimer Disease, Parkinson Disease
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
The goal of this clinical trial is to learn about the application of domestic PET/MR in major brain diseases. The main questions it aims to answer are: Overcome the bottleneck of early accurate diagnosis and treatment in major…
- Conditions
- Alzheimer Disease, Parkinson Disease, Epilepsy, Malignant Brain Tumor
- Trial name
- CAMIND (NCT06092125)
- Testing
- PET/MR
- Where
- China
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Lewy Body Disease, Lewy Body Dementia
Visual Hallucinations in Lewy Body Diseases
The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.
- Conditions
- Lewy Body Disease, Lewy Body Dementia, Parkinson Disease, Parkinson Disease Dementia
- Trial name
- NCT07849413
- Testing
- Behavioral Tasks, MRI/MEG Scans
- Where
- United States
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Parkinson's Disease
Therapeutic Yoga to Improve Function in Parkinson's Disease
This is a single blind, randomized, wait-list controlled, phase II exploratory pilot study.
- Trial name
- NCT02902510
- Testing
- Therapeutic yoga for people with Parkinson's Disease
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Clemson University
Parkinson's Disease, Essential Tremor
Movement Disorder Quantification Algorithm Development
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such…
- Trial name
- NCT01534650
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease, Parkinson-Dementia Syndrome
Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease
The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ([F18]-FDDNP) has a specific affinity for lesions containing tau protein and beta-amyloid The study consists of two phases In a first transversal phase, 8…
- Trial name
- NCT02243982
- Testing
- [F18]-FDDNP
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Parkinson's Disease
Pharmacokinetic Study in Healthy Volunteers
Phase I open, randomized cross-over pharmacokinetic study.
- Trial name
- NOCOFPK2 (NCT02554734)
- Testing
- levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone
- Where
- Finland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson's Disease
How Does STN-DBS Influence Emotional Conflict Decision in Parkinson's Disease: a EEG Study
A large body of evidence points to impairment in the decoding of emotional stimuli in Parkinson's disease (PD). These changes seem to be related to dysfunction of the mesocorticolimbic projections leading to dysfunction of the…
- Trial name
- DBS-EMOTION (NCT02786680)
- Testing
- stroop test in condition DBS off, stroop test in condition DBS on
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Parkinson Disease
Effects of Neuromodulation on Brain Electric Activity of Parkinson's Disease Patients
Parkinson's disease (PD) is a neurodegenerative and progressive movement disorder, whose population incidence is increasing. It is characterized by motor symptoms such as tremor, stiffness and bradykinesia, and non-motor…
- Trial name
- NCT04221659
- Testing
- Transcranial Direct Current Stimulation
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Federal University of Paraíba
Parkinson Disease
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
- Trial name
- NCT06466525
- Testing
- LBT-3627
- Where
- 3 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Longevity Biotech Australia Pty Ltd (subsidiary)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.